title: The role of PET/CT in cervical cancer.
abstract: In locally advanced cervical cancer, (18)F-fluorodeoxyglucose (FDG) positron emission tomography - computed tomography (PET/CT) has become important in the initial evaluation of disease extent. It is superior to other imaging modalities for lymph node status and distant metastasis. PET-defined cervical tumor volume predicts progression-free and overall survival. Higher FDG uptake in both primary and regional lymph nodes is strongly predictive of worse outcome. FDG-PET is useful for assessing treatment response 3 months after completing concurrent chemo-radiotherapy (CRT) and predicting long-term survival, and in suspected disease recurrence. In the era of image-guided adaptive radiotherapy, accurately defining disease areas is critical to avoid irradiating normal tissue. Based on additional information provided by FDG-PET, radiation treatment volumes can be modified and higher doses to FDG-positive lymph nodes safely delivered. FDG-PET/CT has been used for image-guided brachytherapy of FDG-avid tumor volume, while respecting low doses to bladder and rectum. Despite survival improvements due to CRT in cervical cancer, disease recurrences continue to be a major problem. Biological rationale exists for combining novel non-cytotoxic agents with CRT, and drugs targeting specific molecular pathways are under clinical development. The integration of these targeted therapies in clinical trials, and the need for accurate predictors of radio-curability is essential. New molecular imaging tracers may help identifying more aggressive tumors. (64)Cu-labeled diacetyl-di(N(4)-methylthiosemicarbazone) is taken up by hypoxic tissues, which may be valuable for prognostication and radiation treatment planning. PET/CT imaging with novel radiopharmaceuticals could further impact cervical cancer treatment as surrogate markers of drug activity at the tumor microenvironment level. The present article reviews the current and emerging role of PET/CT in the management of cervical cancer.
authors.affiliation: Department of Radiation Oncology, Lausanne University Hospital Lausanne, Switzerland.
authors.forename: Fernanda G
authors.initials: FG
authors.lastname: Herrera
authors.forename: John O
authors.initials: JO
authors.lastname: Prior
keywords: Fluorodeoxyglucose F18; Planning Treatment Volumes; cervical cancer; positron emission tomography; radiation therapy
references.citation: Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1356-65
references.pmid: 16757127
references.citation: Nucl Med Biol. 1996 Nov;23(8):957-80
references.pmid: 9004284
references.citation: Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):307-17
references.pmid: 9607346
references.citation: Curr Oncol. 2010 Jun;17(3):65-9
references.pmid: 20567627
references.citation: Radiology. 2001 Mar;218(3):776-82
references.pmid: 11230656
references.citation: Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):147-53
references.pmid: 18990511
references.citation: Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):91-6
references.pmid: 17189066
references.citation: Nuklearmedizin. 2011;50(6):225-33
references.pmid: 21989840
references.citation: J Nucl Med. 2008 Feb;49(2):201-5
references.pmid: 18199612
references.citation: Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):e29-34
references.pmid: 22503526
references.citation: Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1179-84
references.pmid: 22342094
references.citation: J Clin Oncol. 2002 Feb 1;20(3):680-7
references.pmid: 11821448
references.citation: Gynecol Oncol. 1980 Feb;9(1):90-8
references.pmid: 7353805
references.citation: J Clin Oncol. 2010 Jun 1;28(16):2712-8
references.pmid: 20439646
references.citation: Cancer Res. 1999 Sep 15;59(18):4525-8
references.pmid: 10493500
references.citation: J Clin Oncol. 2008 Dec 1;26(34):5610-7
references.pmid: 18981465
references.citation: Lancet. 2001 Sep 8;358(9284):781-6
references.pmid: 11564482
references.citation: Int J Gynecol Cancer. 2012 May;22(4):667-74
references.pmid: 22398709
references.citation: Cell. 1994 Dec 30;79(7):1157-64
references.pmid: 7528107
references.citation: Clin Genitourin Cancer. 2006 Mar;4(4):299-302
references.pmid: 16729916
references.citation: Eur J Cancer. 2010 Mar;46(4):765-81
references.pmid: 20116997
references.citation: Radiother Oncol. 2006 Jan;78(1):67-77
references.pmid: 16403584
references.citation: J Clin Oncol. 2006 Jan 1;24(1):123-8
references.pmid: 16382121
references.citation: Neuro Oncol. 2009 Dec;11(6):747-56
references.pmid: 19221171
references.citation: J Clin Oncol. 2011 May 1;29(13):1678-85
references.pmid: 21444871
references.citation: J Clin Oncol. 2010 Apr 20;28(12):2108-13
references.pmid: 20308664
references.citation: Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1185-91
references.pmid: 22270171
references.citation: Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1015-23
references.pmid: 9869224
references.citation: BMC Cancer. 2006 Dec 11;6:285
references.pmid: 17156477
references.citation: Cancer Res. 1996 Oct 1;56(19):4509-15
references.pmid: 8813149
references.citation: Br J Cancer. 2011 May 24;104(11):1691-6
references.pmid: 21540865
references.citation: Mol Imaging Biol. 2004 Jan-Feb;6(1):55-62
references.pmid: 15018829
references.citation: Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):935-46
references.pmid: 10705016
references.citation: Future Oncol. 2011 Mar;7(3):339-54
references.pmid: 21417900
references.citation: J Clin Oncol. 2008 May 20;26(15):2558-61
references.pmid: 18487573
references.citation: Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):104-9
references.pmid: 17084549
references.citation: Expert Opin Investig Drugs. 2008 Aug;17(8):1225-35
references.pmid: 18616418
references.citation: Radiother Oncol. 2011 Jan;98(1):139-42
references.pmid: 20971521
references.citation: Radiother Oncol. 2006 Aug;80(2):132-7
references.pmid: 16920212
references.citation: J Vis Exp. 2012 Apr 17;(62):
references.pmid: 22546879
references.citation: J Pathol. 2007 Jul;212(3):316-24
references.pmid: 17503414
references.citation: Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):14-22
references.pmid: 11777618
references.citation: J Nucl Med. 2008 Jul;49(7):1177-82
references.pmid: 18552145
references.citation: Radiother Oncol. 1995 May;35(2):107-17
references.pmid: 7569018
references.citation: J Clin Oncol. 1999 Jan;17(1):41-5
references.pmid: 10458216
references.citation: J Nucl Med. 1999 Jul;40(7):1125-31
references.pmid: 10405131
references.citation: Cancer. 2009 Aug 1;115(15):3548-54
references.pmid: 19472399
references.citation: J Comput Assist Tomogr. 2005 Jul-Aug;29(4):554-9
references.pmid: 16012318
references.citation: J Clin Oncol. 2001 Sep 1;19(17):3745-9
references.pmid: 11533097
references.citation: Int J Cancer. 2010 Dec 15;127(12):2893-917
references.pmid: 21351269
references.citation: Nat Rev Cancer. 2008 Aug;8(8):604-17
references.pmid: 18497750
references.citation: Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):706-12
references.pmid: 15183474
references.citation: Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1507-15
references.pmid: 18164850
references.citation: Radiat Res. 1987 Aug;111(2):292-304
references.pmid: 3628717
references.citation: Mol Imaging Biol. 2007 Sep-Oct;9(5):278-83
references.pmid: 17431727
references.citation: Radiother Oncol. 2005 Mar;74(3):235-45
references.pmid: 15763303
references.citation: Invest New Drugs. 2012 Apr;30(2):749-57
references.pmid: 21049281
references.citation: Radiology. 2006 Jan;238(1):272-9
references.pmid: 16304090
references.citation: Eur J Nucl Med Mol Imaging. 2009 Dec;36(12):1952-9
references.pmid: 19585114
references.citation: Eur J Cancer. 2005 Sep;41(14):2086-92
references.pmid: 16125928
references.citation: Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):406-14
references.pmid: 22687195
references.citation: Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1506-12
references.pmid: 15050330
references.citation: Int J Radiat Oncol Biol Phys. 1994 Apr 30;29(1):9-16
references.pmid: 8175451
references.citation: Int J Gynecol Cancer. 2001 Jul-Aug;11(4):263-71
references.pmid: 11520363
references.citation: Br J Cancer. 2005 Jan 17;92(1):41-6
references.pmid: 15597101
references.citation: Clin Oncol (R Coll Radiol). 2010 Sep;22(7):588-9
references.pmid: 20554439
references.citation: Science. 1994 Apr 22;264(5158):569-71
references.pmid: 7512751
references.citation: Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):985-91
references.pmid: 2808061
references.citation: Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):e35-41
references.pmid: 22543208
references.citation: Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):97-103
references.pmid: 17056201
references.citation: Int J Gynaecol Obstet. 2009 May;105(2):107-8
references.pmid: 19342051
references.citation: Acta Oncol. 2010 Oct;49(7):941-7
references.pmid: 20831481
references.citation: Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1289-97
references.pmid: 15001274
references.citation: Cancer Res. 1998 Apr 1;58(7):1408-16
references.pmid: 9537241
references.citation: Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1077-82
references.pmid: 16024181
references.citation: Radiother Oncol. 2003 Dec;69(3):247-50
references.pmid: 14644483
references.citation: Gynecol Oncol. 2009 Jan;112(1):104-9
references.pmid: 18929403
references.citation: Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):177-81
references.pmid: 16545921
references.citation: Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1140-6
references.pmid: 12419441
references.citation: J Med Chem. 1999 Aug 12;42(16):3033-40
references.pmid: 10447947
references.citation: Cancer. 2005 Dec 1;104(11):2484-91
references.pmid: 16270319
references.citation: Semin Radiat Oncol. 2004 Jul;14(3):249-58
references.pmid: 15254868
references.citation: Gynecol Oncol. 2000 Aug;78(2):187-93
references.pmid: 10926801
references.citation: Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1233-8
references.pmid: 12654432
references.citation: JAMA. 2007 Nov 21;298(19):2289-95
references.pmid: 18029833
references.citation: Cancer. 2007 Oct 15;110(8):1738-44
references.pmid: 17786947
references.citation: Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1085-91
references.pmid: 19880262